Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Hafner-Blumenstiel, Verena [VerfasserIn]   i
 Czock, David [VerfasserIn]   i
 Burhenne, Jürgen [VerfasserIn]   i
 Riedel, Klaus-Dieter [VerfasserIn]   i
 Bommer, Jürgen [VerfasserIn]   i
 Mikus, Gerd [VerfasserIn]   i
 Machleidt, Christoph [VerfasserIn]   i
 Weinreich, Thomas [VerfasserIn]   i
 Haefeli, Walter E. [VerfasserIn]   i
Titel:Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration
Verf.angabe:Verena Hafner, David Czock, Jürgen Burhenne, Klaus-Dieter Riedel, Jürgen Bommer, Gerd Mikus, Christoph Machleidt, Thomas Weinreich, Walter E. Haefeli
E-Jahr:2010
Jahr:1 June 2010
Umfang:7 S.
Fussnoten:Gesehen am 15.06.2023
Titel Quelle:Enthalten in: Antimicrobial agents and chemotherapy
Ort Quelle:Washington, DC : Soc., 1972
Jahr Quelle:2010
Band/Heft Quelle:54(2010), 6, Seite 2596-2602
ISSN Quelle:1098-6596
Abstract:Sulfobutylether-beta-cyclodextrin (SBECD), a large cyclic oligosaccharide that is used to solubilize voriconazole (VRC) for intravenous administration, is eliminated mainly by renal excretion. The pharmacokinetics of SBECD and voriconazole in patients undergoing extracorporeal renal replacement therapies are not well defined. We performed a three-period randomized crossover study of 15 patients with end-stage renal failure during 6-hour treatment with Genius dialysis, standard hemodialysis, or hemodiafiltration using a high-flux polysulfone membrane. At the start of renal replacement therapy, the patients received a single 2-h infusion of voriconazole (4 mg per kg of body weight) solubilized with SBECD. SBECD, voriconazole, and voriconazole-N-oxide concentrations were quantified in plasma and dialysate samples by high-performance liquid chromatography (HPLC) and by HPLC coupled to tandem mass spectrometry (LC-MS-MS) and analyzed by noncompartmental methods. Nonparametric repeated-measures analysis of variance (ANOVA) was used to analyze differences between treatment phases. SBECD and voriconazole recoveries in dialysate samples were 67% and 10% of the administered doses. SBECD concentrations declined with a half-life ranging from 2.6 ± 0.6 h (Genius dialysis) to 2.4 ± 0.9 h (hemodialysis) and 2.0 ± 0.6 h (hemodiafiltration) (P < 0.01 for Genius dialysis versus hemodiafiltration). Prediction of steady-state conditions indicated that even with daily hemodialysis, SBECD will still exceed SBECD exposure of patients with normal renal function by a factor of 6.2. SBECD was effectively eliminated during 6 h of renal replacement therapy by all methods, using high-flux polysulfone membranes, whereas elimination of voriconazole was quantitatively insignificant. The SBECD half-life during renal replacement therapy was nearly normalized, but the average SBECD exposure during repeated administration is expected to be still increased.
DOI:doi:10.1128/aac.01540-09
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1128/aac.01540-09
 Volltext: https://journals.asm.org/doi/10.1128/aac.01540-09
 DOI: https://doi.org/10.1128/aac.01540-09
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:1849819637
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69085974   QR-Code
zum Seitenanfang